The Prescribing Information is the primary source of information on the known and potential risks of ocrelizumab for relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).

As of August 2019, more than 120,000 patients1 with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 120,000 patient-years.2

The following ocrelizumab global safety updates are available. Click below to learn more:

Updated Safety Analysis

Additional Topics of Interest

Post-marketing Commitments

Indication:

Ocrelizumab is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis.

 

Report an Adverse Event:
Phone: (888) 835-2555
Hours: 24 hrs/day, 7 days/week

Medical Communications:
Submit a question online
Phone: (800) 821-8590
Hours: Monday - Friday, 5am - 5pm PT

Contact an MSL:
Request follow-up with a Genentech medical science liaison (MSL)

References:

1.

Genentech data on file: 31 July 2019

2.

Genentech data on file: 31 July 2019, post-marketing experience; January 2019, clinical trials data cut-off